Literature DB >> 19049436

High incidence of tuberculosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies.

A C Hesseling1, M F Cotton, T Jennings, A Whitelaw, L F Johnson, B Eley, P Roux, P Godfrey-Faussett, H S Schaaf.   

Abstract

BACKGROUND: There are limited population-based estimates of tuberculosis incidence among human immunodeficiency virus (HIV)-infected and HIV-uninfected infants aged < or =12 months. We aimed to estimate the population-based incidence of culture-confirmed tuberculosis among HIV-infected and HIV-uninfected infants in the Western Cape Province, South Africa.
METHODS: The incidences of pulmonary, extrapulmonary, and disseminated tuberculosis were estimated over a 3-year period (2004-2006) with use of prospective representative hospital surveillance data of the annual number of culture-confirmed tuberculosis cases among infants. The total number of HIV-infected and HIV-uninfected infants was calculated using population-based estimates of the total number of live infants and the annual maternal HIV prevalence and vertical HIV transmission rates.
RESULTS: There were 245 infants with culture-confirmed tuberculosis. The overall incidences of tuberculosis were 1596 cases per 100,000 population among HIV-infected infants (95% confidence interval [CI], 1151-2132 cases per 100,000 population) and 65.9 cases per 100,000 population among HIV-uninfected infants (95% CI, 56-75 cases per 100,000 population). The relative risk of culture-confirmed tuberculosis among HIV-infected infants was 24.2 (95% CI, 17-34). The incidences of disseminated tuberculosis were 240.9 cases per 100,000 population (95% CI, 89-433 cases per 100,000 population) among HIV-infected infants and 14.1 cases per 100,000 population (95% CI, 10-18 cases per 100,000 population) among HIV-uninfected infants (relative risk, 17.1; 95% CI, 6-34).
CONCLUSIONS: This study indicates the magnitude of the tuberculosis disease burden among HIV-infected infants and provides population-based comparative incidence rates of tuberculosis among HIV-infected infants. This high risk of tuberculosis among HIV-infected infants is of great concern and may be attributable to an increased risk of tuberculosis exposure, increased immune-mediated tuberculosis susceptibility, and/or possible limited protective effect of bacille Calmette-Guérin vaccination. Improved tuberculosis control strategies, including maternal tuberculosis screening, contact tracing of tuberculosis-exposed infants coupled with preventive chemotherapy, and effective vaccine strategies, are needed for infants in settings where HIV infection and tuberculosis are highly endemic.

Entities:  

Mesh:

Year:  2009        PMID: 19049436     DOI: 10.1086/595012

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  72 in total

Review 1.  Unresolved antiretroviral treatment management issues in HIV-infected children.

Authors:  Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  Suppressed type 1, type 2, and type 17 cytokine responses in active tuberculosis in children.

Authors:  N Pavan Kumar; R Anuradha; R Suresh; R Ganesh; Janani Shankar; V Kumaraswami; Thomas B Nutman; Subash Babu
Journal:  Clin Vaccine Immunol       Date:  2011-09-28

3.  CT features of lymphobronchial tuberculosis in children, including complications and associated abnormalities.

Authors:  Susan Lucas; Savvas Andronikou; Pierre Goussard; Robert Gie
Journal:  Pediatr Radiol       Date:  2012-05-30

4.  Tuberculosis and AIDS co-morbidity in children: linkage of databases from Espirito Santo State, Brazil.

Authors:  Angelica E Miranda; Reynaldo Dietze; Ethel L Maciel; Thiago N Prado; Antonio L Caus; Murilo M Silva; Jonathan E Golub
Journal:  J Trop Pediatr       Date:  2010-09-28       Impact factor: 1.165

5.  Risk factors for mortality in Malawian children with human immunodeficiency virus and tuberculosis co-infection.

Authors:  W C Buck; D Olson; M M Kabue; S Ahmed; L K Nchama; A Munthali; M C Hosseinipour; P N Kazembe
Journal:  Int J Tuberc Lung Dis       Date:  2013-11       Impact factor: 2.373

6.  Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.

Authors:  B Zeldow; S Kim; G McSherry; M F Cotton; P Jean-Philippe; A Violari; R Bobat; S Nachman; L M Mofenson; S A Madhi; C Mitchell
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

7.  Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Authors:  A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch
Journal:  HIV Med       Date:  2015-02-03       Impact factor: 3.180

Review 8.  Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents.

Authors:  Brian S Eley; Tammy Meyers
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 9.  Tuberculosis susceptibility and protection in children.

Authors:  Robindra Basu Roy; Elizabeth Whittaker; James A Seddon; Beate Kampmann
Journal:  Lancet Infect Dis       Date:  2018-10-12       Impact factor: 25.071

10.  Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children.

Authors:  Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.